News

The U.S. Food and Drug Administration (FDA) has approved the first generic equivalent to AstraZeneca’s Symbicort (budesonide and formoterol fumarate dihydrate) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The generic, produced by Mylan Pharmaceuticals now part of Viatris, will be available as a metered-dose inhaler. It is intended…

Propeller Health has announced three new initiatives aiming to broaden the application of its technology, which connects a sensor to inhalers, allowing for detailed tracking of treatment in chronic obstructive pulmonary disease (COPD) and asthma. The goal, according to Propeller, is to implement “new solutions to bring [this]…

Papa, an at-home companionship and support platform, has partnered with Highmark Wholecare, a managed care organization, to address the social needs of Pennsylvania’s most vulnerable populations, including chronic obstructive pulmonary disease (COPD) patients and people at risk of isolation. The collaboration, touted as a new approach to…

Infection with rhinovirus, a virus that causes the common cold, combined with long-term exposure to cigarette smoke — two risk factors associated with symptom worsening in people with chronic obstructive pulmonary disease (COPD) — can significantly affect lung structure, a study in a mouse model has found. The study,…

Pulmonary rehabilitation programs can ease shortness of breath, and improve exercise capacity and quality of life in people with chronic obstructive pulmonary disease (COPD), according to a recent meta-analysis. Additionally, the study revealed that mind-body exercises, such as tai chi and yoga, can significantly improve lung function in these…

High levels of the progenitor marker LGR6 in lung samples of chronic obstructive pulmonary disease (COPD) patients may lock the lungs in a pro-regenerative state and ultimately trigger the exhaustion of lung progenitor cells, a study reports. According to researchers,  this ultimately limits the ability of the lungs to…

ENA Respiratory is developing its first-in-class, broad-spectrum antiviral nasal spray — known as INNA-051 — for populations at risk of developing complications from respiratory viral infections, including COVID-19. Now, the Australian company is teaming up with the COPD Foundation, a nonprofit with a mission to improve the…

Respira Labs has raised $2.8 million to help develop a wearable device that uses sound to evaluate lung function in people with respiratory conditions, such as chronic obstructive pulmonary disease (COPD), asthma, and COVID-19. “We’re a U.S.-based startup excited to be making strides in a highly competitive space…

The U.S. Food and Drug Administration (FDA) has given final approval to Zydus Pharmaceuticals to start marketing roflumilast tablets at a dose of 500 micrograms (mcg), according to a company press release. Roflumilast tablets are a generic version of oral Daliresp, manufactured by AstraZeneca. Like the brand-name medicine,…

The U.S. Food and Drug Administration (FDA) has approved Lupin Limited’s generic form of Brovana (arformoterol tartrate) for treating bronchoconstriction in people with chronic obstructive pulmonary disease (COPD). Like the name-brand medicine sold by Sunovion Pharmaceuticals, the new generic is indicated for long-term maintenance treatment, according to…